Transgene

• Issuance of 20,816,366 new shares, c. 33.3% of Transgene pre-deal outstanding share capital
• Subscription price of €2.34 per share, 15.8% discount to TERP based on the Euronext Paris closing price on 13 June 2019 
• 17,520,428 new shares were subscribed on a non-reducible basis, representing approximately 84% of the total number of new shares
• Demand on a reducible basis amounted to 6,285,626 new shares, 52% of which will be allocated. As a result, 3,295,938 new shares will be issued to serve the reducible basis demand, representing approximately 16% of the total number of new shares
• Both Institut Mérieux and Dassault Belgique Aviation have committed to subscribe to new shares to maintain its stake in Transgene
• Transaction proceeds will be used to reinforce the Company’s financial structure until 2022, in particular to significantly progress its novel myvac™ and Invir.IO™ product platforms and to complete the clinical development plan for its more mature assets
• Transgene is a long-standing client of Kempen. This successful offering marks Kempen’s sixth Life Sciences ECM transaction in 2019

Transgene is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilise viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine against HPV-positive head and neck cancers. The Company has several other programs in clinical development, including TG1050 (a therapeutic vaccine for the treatment of chronic hepatitis B) and TG6002 (an oncolytic virus for the treatment of solid tumors).